HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase A, members will obtain distinct doses and schedules of oral ABBV-744 pill to discover Risk-free dosing regimen. Additional contributors might be enrolled for the recognized monotherapy dosign program. In Section B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will receiv